Banca Mediolanum SpA (BMED) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Banca Mediolanum SpA stock €10.45, price €23.32, that is 55.2% below the price, quality 53 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range €4.48 – €24.42 · fair‑value band €9.68 – €13.31 · the €23.32 price screens above the €10.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 1, 2026.
Follow Banca Mediolanum SpA in your weekly email
Every Wednesday you see whether Banca Mediolanum SpA is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Banca Mediolanum S.p.A. engages in the provision of various banking products and services in Italy. It offers current accounts; deposits products; and mortgage and personal loans.
Show moreShow less
The company also provides credit cards, debit cards, and prepaid cards; investment products, such as mutual funds, unit linked policies, investment strategies, trading services, asset management services, social security, and bond issues and certificates; and insurance policies, including health and personal, life, serious illness, and autonomy protection, as well as protection assistance, and home and family protection.
In addition, it offers SelfyCare Pet for reimbursement of veterinary expenses; SelfyCare Travel for assistance and coverage for risks arising during trips; and SelfyCare LifeProject for a specific life project. Banca Mediolanum S.p.A. founded in 1982 and is headquartered in Basiglio, Italy.
Stock analysis
Banca Mediolanum SpA (BMED) currently trades at €23.32, while our model-based Fair Value estimate is €10.45, 55% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of €10.45 per share, and 0 of the 6 models we run sit above the €23.32 price.
Bear case: the Asset-Based group reads lowest at €3.86, and 6 of the 6 models stay below the price. Data coverage for this calculation is high.
Scenario range: €9.68 (bear) to €13.31 (bull), the price of €23.32 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Financial Services sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Banca Mediolanum SpA reported revenue of €2.4B in FY2025 versus €5.7B in FY2021, a compound −19.2%/yr. Reported net income was €1.2B in FY2025, compounding +14.8%/yr from FY2021.
Key figures
Market cap €17.4B Large · P/E ratio 13.2 · P/S ratio 6.79 · EPS (TTM) €1.77 · Dividend yield 5.3% · Net margin 51.4% · Return on equity 30.1% · Return on assets (EBIT) 1.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 80 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −34% fair-value upside, at −55%, BMED screens richer than that median.
Fair Value models
Bear€9.68Fair Value €10.45Bull€13.31
Price €23.32 · Downside -55.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€0.4586 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.39/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.7%
Start year 2020 (pandemic). Over 10 years: −6.1% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +19.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.0%
Dividend (yield on the price)5.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.16.9% vs 12.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 59%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 8.5%/yr over ~10Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
⚠ Rate on operating basis: 2025 sits 51% above its own trend.
News mood ⓘNews mood, the average tone of recent news (15 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: High ROE and margins reflect operational efficiency as the main strength, yet scant public signals leave limited evidence of a durable moat for this regional bank.
Main risk: Digital-first neobanks such as Revolut, Hype and N26 with low-cost app-based accounts and investments might draw away clients preferring simple online banking and reduce demand for Mediolanum's Family Banker advisory model.
Bull case: Mediolanum could strengthen its hybrid model by using proprietary AI tools to support Family Bankers, making human advice more efficient and retaining clients who value personal relationships over pure digital offerings.
Bear case: If neobanks and digital platforms from larger banks continue expanding in Italy, Mediolanum might see slower net inflows into asset management and pressure on fees as clients shift to cheaper, self-service alternatives.
Banca Mediolanum continues to draw strong net inflows, with a rising share from recurring asset management contributions that support gradual client investing over time. Our models currently see the stock as overvalued despite this momentum. Does the focus on quality recurring flows deliver enough durable stability to justify the valuation, or does it expose limits in maintaining the pace?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Banks - Regional · 1002 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score53 · Below median
Fair Value upside−55.2% · Bottom 25%
Profitability
Return on equity (12 months)30.1% · Top 25%
Return on assets1.4% · Top 25%
Net margin (12 months)51.4% · Top 25%
Operating margin (12 months)58.4% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)29.0% · Top 25%
Dividend yield (12 months)5.3% · Top 25%
Balance sheet
Debt / equity0.14× · Below median
Valuation Multiplesvs Banks - Regional median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Banca Mediolanum SpA (BMED) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of €10.45 versus a price of €23.32, about 55% lower (overvalued).
What is the fair value of BMED?
Our model-based fair value for Banca Mediolanum SpA is €10.45 (as of Nov 1, 2026), built from audited fundamentals. The current price: €23.32.
What is the quality score of BMED?
Banca Mediolanum SpA has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Banca Mediolanum SpA (BMED)?
Our model-based price target is the fair value of €10.45 (as of Nov 1, 2026) from 6 valuation models. Cautious scenario €9.68, optimistic scenario €13.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Banca Mediolanum SpA stock forecast for 2026?
Our models put fair value at €10.45, about 55% lower versus a price of €23.32 (overvalued). Cautious scenario €9.68, optimistic scenario €13.31. The calculation is refreshed regularly with new filings.
What is the revenue of Banca Mediolanum SpA (BMED)?
Banca Mediolanum SpA reported trailing-twelve-month revenue of about €2.6B (latest available figure, as of Nov 1, 2026).
Does Banca Mediolanum SpA pay a dividend?
Banca Mediolanum SpA currently shows a dividend yield of 5.27% relative to its recent price (as of Nov 1, 2026).
What is the intrinsic value of Banca Mediolanum SpA (BMED)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Banca Mediolanum SpA it is €10.45 per share (as of Nov 1, 2026), against a price of €23.32. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is Banca Mediolanum SpA stock overvalued or undervalued in 2026?
As of Nov 1, 2026, BMED trades above its calculated fair value: price €23.32, fair value €10.45, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BMED?
No. The price is what the market pays today (€23.32); the fair value is what the company's own numbers justify (€10.45). For Banca Mediolanum SpA the two are €12.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Banca Mediolanum SpA worth?
The market values Banca Mediolanum SpA at about €17.4B (market capitalisation, as of Nov 1, 2026). Per share that is €23.32; our models calculate a fair value of €10.45 per share.
What do the bullish and bearish scenarios say about BMED?
Our models span a range for Banca Mediolanum SpA: cautious scenario €9.68, base €10.45, optimistic €13.31 per share (as of Nov 1, 2026, price €23.32). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BMED?
Banca Mediolanum SpA trades at a price-to-earnings ratio of 13.2 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €10.45 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings: 11.6. Other multiples: PEG 0.2, P/B 3.9, P/S 6.8, EV/EBITDA 11.9.
What is the PEG ratio of BMED?
The PEG ratio of Banca Mediolanum SpA is 0.23 (P/E divided by earnings growth, as of Nov 1, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Banca Mediolanum SpA (BMED)?
Balance-sheet figures for Banca Mediolanum SpA (as of Nov 1, 2026): return on equity 30.1%, debt of 0.14 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is BMED from its 52-week high?
Banca Mediolanum SpA trades at €23.32, about 5% below its 52-week high of €24.42 and 47% above the low of €15.90 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of €10.45 is for.
Which stocks are comparable to Banca Mediolanum SpA?
From the same area (Financial Services) we also value China Merchants Bank Co, DBS Group, UniCredit S.p.A, Mizuho Financial Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Banca Mediolanum SpA stock attractive at the current price?
The data as of Nov 1, 2026: price €23.32, calculated fair value €10.45 (−55%), Quality Score 53/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BMED calculated?
We run Banca Mediolanum SpA through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €10.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Banca Mediolanum SpA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Banca Mediolanum SpA (BMED)?
The closing price on Nov 5, 2026 was €23.32. Our model-based fair value is €10.45, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Banca Mediolanum SpA right now?
The price sits above even our optimistic bull case (€13.31). The favourable scenario is already priced in. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Where does the earnings growth of Banca Mediolanum SpA (BMED) come from?
Earnings per share at Banca Mediolanum SpA grew +12.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share −6.9 %, EBIT margin +20.0 %, tax rate +0.2 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Banca Mediolanum SpA
How large is the market capitalisation of Banca Mediolanum SpA (BMED)?
The market capitalisation of Banca Mediolanum SpA is €17.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Banca Mediolanum SpA (BMED)?
The price-to-sales ratio of Banca Mediolanum SpA is 6.79 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Banca Mediolanum SpA (BMED)?
Earnings per share at Banca Mediolanum SpA are €1.77 (price ÷ EPS = P/E 13.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Banca Mediolanum SpA (BMED)?
The dividend yield of Banca Mediolanum SpA is 5.3% (payout 69.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Banca Mediolanum SpA (BMED)?
The net margin of Banca Mediolanum SpA is 51.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Banca Mediolanum SpA (BMED)?
The return on equity (ROE) of Banca Mediolanum SpA is 30.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Banca Mediolanum SpA (BMED)?
On an EBIT basis the return on assets of Banca Mediolanum SpA is 1.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Banca Mediolanum SpA (BMED)?
The operating margin of Banca Mediolanum SpA is 58.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Banca Mediolanum SpA (BMED)?
Revenue at Banca Mediolanum SpA is growing +29.0% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Banca Mediolanum SpA (BMED)?
Earnings per share at Banca Mediolanum SpA are growing +19.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Banca Mediolanum SpA (BMED) generate?
The free cash flow of Banca Mediolanum SpA is €346M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Banca Mediolanum SpA (BMED) carry?
The net debt of Banca Mediolanum SpA is €2.9B (fiscal year 2025, ≈ 8.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Banca Mediolanum SpA in the live analysis
One click puts Banca Mediolanum SpA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 1, 2026